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Abstract. VRK (vaccinia-related kinase) is a group of three 
proteins in the human kinome. These proteins, mainly VRK1 and 
VRK2, have been studied in the context of their substrates and 
interacting proteins in order to identify and characterize their 
signaling pathway, as well as their effect on other signaling 
pathways. VRK1 is mostly a nuclear kinase that specifically 
phosphorylates p53, c-Jun, ATF2, CREB, BAF and histone H3. 
VRK1 is an early response gene and is implicated in regulation of 
cell cycle progression. VRK1 is activated in response to DNA 
damage phosphorylating p53, which is stabilized and activated; this 
active p53 induces a downregulatory mechanism of VRK1 that 
permits the reversal of p53 induced effects. The activity of nuclear 
VRK1 is regulated by its interaction with the Ran small GTPase. 
Also, VRK1 is a downstream component of the signaling pathway 
of MEK-Plk3 that induces Golgi fragmentation in mitosis.  VRK2  
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has two isoforms; VRK2A is cytosolic and bound to endoplasmic reticulum and 
mitochondrial membranes. VRK2B is a shorter isoform free in cytosol and nucleus. 
VRK2A affects cellular signaling by interaction with scaffold proteins, as JIP1. The 
JIP1-VRK2A signalosome blocks the incorporation of JNK, preventing its activation, 
and thus reducing the stress response to inflammatory cytokines as interleukin-1β and 
to hypoxia. 
 
1. The vaccinia-related kinase (VRK) family 
 
 The completion of the human genome project has led to the identification 
of 518 proteins that constitute the human kinome [1]. Approximately half of 
them are not well characterized regarding the signaling pathways in which 
they are integrated, and their biological functions. But in most likelihood they 
can probably account for the specificity and regulation of many biological 
functions.  VRK (vaccinia-related kinases) were classified as a new group of 
Ser-Thr kinases in the human kinome [1], and originally were identified as 
two human EST, VRK1 and VRK2, which have homology to catalytic region 
of the B1R kinase of vaccinia virus [2] that is expressed early in viral 
infection since it is required for viral DNA replication [3-5]. The VRK gene 
family appeared late in evolution. In lower eukaryotes, D. melanogaster 
(NHK-1) and C. elegans (Vrk1), there is only one member, and no ortholog 
has been identified in unicellular eukaryotes, like yeasts S. cerevisiae or S. pombe. 
In mammals there are three members, two of which (VRK1 and VRK2) are 
catalytically active [6-8], and a third one, VRK3, is not active and might 
function as a scaffold protein [9]. The VRK catalytic domain is distantly 
related to the casein kinase group, forming an early divergent branch in the 
human kinome [1], but the conservation of the kinase domain is weak and has 
substitutions in several key residues in this domain [10]. These proteins 
maintain the structure of the kinase domain, but the rest of the protein is very 
divergent among them, suggesting that the CK1-like catalytic domain 
recombined early in evolution with other proteins to form a divergent protein 
family with new regulatory properties, affecting interactions, regulation, and 
subcellular localization. In one of these recombination events the kinase 
domain was picked up by pox viruses (vaccinia, variola, smallpox) and 
generated the B1R protein, which is the only kinase in poxviruses genome; 
B1R is required for poxvirus replication and its inactivating mutations can be 
partially recovered by overexpression of mammalian VRK1, or VRK2 
proteins, indicating that in poxvirus there was an additional functional 
divergence due to viral life requirement [11]. Structurally, the three VRK 
proteins differ in their regulatory region located C-terminal for VRK1 and 
VRK2 and N-terminal for VRK3. These regulatory regions are unrelated 
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among them and have no homology to any known feature identified in other 
proteins. The length of the regulatory region is variable. It is approximately 
one hundred amino acids in VRK1 and two hundred aminoacids in VRK2, 
thus their subcellular localization and regulation is likely to be different 
among mammalian VRK proteins and those of lower eukaryotes. The relative 
conservation of catalytic domain of VRK proteins indicates they can have an 
overlap of potential substrates. 
 The catalytic domain of these kinases have some key substitutions which 
make them differ from other closely related kinases, nevertheless two of them 
VRK1 and VRK2 are catalytically active and have a 56 % sequence identity 
[6, 8, 12]. These differences might be exploited for the design of VRK 
specific inhibitors [13], which may be achieved by determination of their 
crystal structure. The crystal structure of the catalytic domain of VRK2 and 
VRK3, with 38 % sequence identity and without any significant difference, 
has been determined providing the framework for future inhibitor 
development [10]. 
 Human VRK1 gene is located on the chromosomal region 14q32.2. This 
gene has a polymorphism, marker rs722869, that in combination with other 
nine polymorphisms in other genes has proven very useful and is included in 
the most informative set to study the identification of human continental 
population structure and genetic ancestry [14]. VRK1 gene expression has 
been studied in hematopoietic murine development, and its highest 
expression coincides with the time of maximum cellular expansion in days 
E11.5  to  E13.5 [15].   Endogenous  VRK1  protein  is  detected  in  different 
 
 
 
Figure 1. Structure of the three human VRK proteins. ATP: ATP binding site; KD: 
kinase domain; Plk: consensus target for Plk3. NLS: nuclear localization signal. BAB: 
Basic-acid-basic region. TM: transmembrane region. 
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intracellular compartments, suggesting that localization is regulated and that 
it might play different functional roles depending on its localization. VRK1 
has a canonical nuclear localization signal (KKRKK) in residues 356 – 360, 
which accounts for its nuclear localization [6, 8]. In interphase the 
endogenous VRK1 has a granular aspect, probably forming aggregates, 
dispersed within the nucleus, and in mitosis it is dispersed throughout the cell 
and does not bind to chromatin. In some cell types the endogenous VRK1 
protein is mostly cytosolic presenting a particulate appearance, and a minor 
fraction is nuclear [16], but the underlying cause is unknown. Also there is a 
subpopulation in the Golgi apparatus where VRK1 colocalizes with giantin 
where it participates in the control of Golgi fragmentation, and perhaps in 
VRK1 recycling [17]. This differential distribution is tissue specific [16]. 
These different locations of human VRK1 are also detected in human normal 
tissue biopsies. For example in testes and esophagus VRK1 is detected as 
nuclear with all antibodies. However in small intestine or kidney, a nuclear 
and a cytosolic subpopulation are detected depending on the antibody used 
[16]. The factors determining, and regulating, these different subcellular 
localizations are unknown.  
 The human VRK2 gene has 14 exons and can generate two different 
transcripts by alternative splicing, one lacking exon 13 that contains a 
termination codon, encoding two proteins of 508 (VRK2A) or 397 (VRK2B) 
aminoacids respectively. The largest protein is called VRK2A, and the other 
is VRK2B [12], both are identical up to residue 393 and have a common 
kinase domain. The VRK2A protein has, at the end of its carboxy terminus, a 
hydrophobic region of 17 aminoacids that anchors the protein to membranes 
in endoplasmic reticulum and mitochondria. VRK2A colocalizes with 
calreticulin and calnexin indicating its presence in the endoplasmic reticulum 
[12]; it also colocalizes with mitotracker, a lipidic marker of mitochondria 
[12]. VRK2B, lacking its hydrophobic tail, is free in the cytosol and the 
nucleus of the cell. The shorter isoform B is more similar in size to VRK1, 
lacking the membrane anchor sequence, and detected in those cells where 
VRK1 is mostly cytosolic, suggesting they might have some functional 
redundancy, but how their expression is coordinated is not known. Therefore, 
although both proteins might have similar or identical kinase properties, their 
natural substrates may be different due to their different subcellular 
localization. Additional variants of VRK2 have been identified by RT-PCR, 
but the expected corresponding proteins have not been detected and may 
represent splicing intermediates. Many cell types have been studied for the 
expression of both isoforms, such as normal B-cells, several lymphoma cell 
lines and several frequently used carcinoma cell lines such as HeLa, A549, 
H1299, MCF7, among others. All of them expressed both messages [12]. All 
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of them express VRK2A protein, but the level of the VRK2B protein was 
variable, and in some cell lines was not detectable [12]. 
 The human VRK3 gene is located on 19q13.33, and codes for a protein 
with a degenerate kinase domain located in the carboxy terminal region that 
has no kinase activity due to critical aminoacid substitutions [8]. Its crystal 
structure has revealed important structural differences that make it unable to 
bind ATP [10]. VRK3 non-functional kinase-dead domain maintains its 
overall structure so that it can function as scaffold for other proteins [10]. The 
VRK3 protein is detected in the nucleus and has a bipartite nuclear 
localization signal [8, 9].  
 In humans the expression of VRK proteins has been detected in all 
tissues studied; but not all cells in a tissue express these proteins. The reason 
for this heterogeneous expression is not yet known, but it may be associated 
to the proliferation and differentiation state of individual cells. In normal 
epithelium higher levels are detected near the basal layer, and the intensity of 
the signal decreases as the cell matures [18]. 
 
2. Biological roles of VRK proteins 
 
 The biological information available on the three VRK proteins is very 
limited, and most of it was obtained by studying the human proteins in two 
main directions. One of them implies the characterization of the signaling 
pathway in which VRK proteins are implicated, either by substrate 
identification or by interaction with other proteins. The other is directed at 
their effect on some biological response, such as hypoxia, interleukin1β or 
DNA damage. In both situations it is expected that information will expand 
as these proteins acquire more relevance in the context of tumor biology, and 
start to attract more attention. In the case of VRK1 some of its targets have 
been identified, including several transcription factors (Fig. 2), which can 
serve as starting points to characterize the VRK pathway by itself, or their 
interaction with other pathways. 
 In this review we will summarized the different biological processes 
where VRK proteins have been shown to participate. 
 
3. VRK proteins and cell signaling 
 
3.1. VRK2 downregulates the response to hypoxia or interleukin-1β 
mediated by JNK 
 
 Many biological processes induced by growth factors, stress responses 
send signals that activate gene expression. These signals are channeled by a 
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protein complex of mitogen-associated protein kinases (MAPK) which are 
activated by two additional kinases, MAPKK and MAPKKK, ordered as 
consecutive steps. MAP kinases represent the core of multiple signaling 
pathways in response to a variety of stimuli, ranging from growth factors to 
stress responses. The response implies multiple biological effects such as 
proliferation, apoptosis, growth arrests and senescence among others [19, 20]. 
For each of these steps there are multiple kinases, making up multiple 
combinations that are very likely to determine the specificity of the 
responses. The three kinases are often anchored on a scaffold protein; the best 
known are JIP1, of which there are four members, and KSR1 [21]. But there 
are also other less well known scaffolds. The levels and subcellular 
localization of scaffold proteins are critical to determine the distribution of a 
signal among different signaling pathways, and the asymmetry of this signal 
distribution can determine the final biological effect. These complexes might 
be further regulated by additional proteins that might interact, activate or 
inhibit the signal transmission; among these proteins are the two VRK2 
isoforms. Therefore signal specificity is likely to be determined by 
interactions between components of the core signaling pathway with other 
proteins, most of which have not yet been identified, but is an emerging field. 
Among these proteins, VRK2A and VRK3 have been shown to interact and 
regulate MAP kinase signaling in response to different types of stimulation. 
 
3.2. VRK2 downregulates MAP kinase signaling and JNK activation 
 
 Many biological processes are controlled by regulation of the activity of 
mitogen-activated protein kinases which function like a central hub where 
signals are received and distributed to exert specific roles. MAPK (mitogen-
activated protein kinases) are implicated in a large number of cellular 
responses to growth factors and stress signals of different types. MAPK 
signals are transmitted by a complex of three consecutive kinases and for 
each step there are several possibilities. The combination of these kinases 
contributes to signal specificity. The three consecutive MAP kinases are 
assembled on scaffold proteins, of which there are several types [21]. These 
modules permit the organization of specific signal transmission and can be 
further modulated by specific interactions with other proteins. One of these 
new regulators is VRK2, which by its interaction with scaffold–MAPK 
complexes can alter the balance between different pathways responding to a 
common signal. Signals regulating proliferation are mainly transmitted by the 
RAF-MEK-ERK proteins assembled on the KSR1 scaffold, while signals 
implicated in stress responses are channeled by the TAK1-MKK4/7-JNK 
complex assembled on JIP proteins [21]. The effect of VRK proteins on 
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signaling by scaffold proteins has been studied using two different 
experimental systems; one based on the response to stress mediated by the 
JNK (c-Jun N-terminal kinase) pathway and the other in response to growth 
factors such as EGF and mediated by the ERK pathway. The best 
characterized one is the complex assembled on JIP1. JIP1 interacts with JNK 
and MKK4, or MKK7, as the third and second kinase respectively. However, 
responses to a common stimulation using this complex may vary depending 
on cell type, and the reasons for the difference are not known, but are likely 
to be related to additional proteins which might modulate the signalosome or 
signaling complex. The JIP1 scaffold protein is usually thought of as a 
monomer to which different kinase can bind. However, it is known that JIP1 
can also be associated to membranes and form large complexes [22]. In our 
laboratory we have identified that JIP1 form complexes with a size of 1200 
kDa, which includes the VRK2A protein [23, 24]. These complexes can 
incorporate VRK2, and the composition of the complex can be altered if cells 
are stimulated [23].  
 
 
 
Figure 2. Model of the complexes assembled on the JIP1 scaffold protein which can 
incorporate VRK2 protein and is modulated by interleukin-1β or hypoxia.  
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 The VRK2A protein subpopulation that is anchored on the endoplasmic 
reticulum (ER) [12], colocalizes with JIP1 on the ER which suggest that they 
can interact and modulate MAPK signaling [24]. JIP1 by interacting with 
ER-anchored VRK2 can be incorporated and form larger complexes; JIP1 up 
to now has been thought of as a monomer, and by this incorporation in 
membrane complexes JIP1 can be compartmentalized instead of being free in 
the cytosol. The formation of these complexes provides the cell with two 
different signaling alternatives, depending on location and aggregation state, 
and probably with different substrates. The formation of the signalosome is 
likely to be assembled on VRK2A protein anchored to membranes, because it 
is not formed by the VRK2B isoform that is free in the cytosol and nuclei 
(Fig. 2). The presence of VRK2A is a major requirement to induce the 
oligomerization state and assembly of the signalosome. In the presence of 
VRK2A complexes are very large (1000 kDa), but when VRK2A was 
knocked down the complexes were disassembled, and many of its 
components were detected as free or forming smaller and incomplete 
complexes [23, 24]. The effect of VRK2-JIP1 interaction has been studied 
under two types of stimulation, one in response to the inflammatory 
interleukin-1β (IL-1 β)[24] and the other in response to hypoxia [23], IL-1 β  
and hypoxia induce the formation of a large complexes of more than 1000 
kDa, known as signalosomes, and containing MAPK and JIP1 protein, and 
among its components is present the VRK2A [23, 24]. In the complex 
VRK2A directly interacts with JIP1 and TAK1. The stable interaction of 
VRK2A with JIP1 can alter the composition of MAPK bound to JIP1. 
Binding of VRK2A to JIP1 does not affect JIP1 interaction with TAK1 or 
MKK7, but reduces its binding to JNK, and thus limits the potential 
activation of c-Jun dependent transcription, which can not be activated 
because JNK is inactive (Fig. 2).  
 
3.3. VRK3 downregulates ERK activity by interaction with the 
VHR phosphatase 
 
 The nuclear VRK3 protein is able to downregulate ERK signaling by a 
mechanism different from the one involving VRK2 and MAPK. Because 
VRK2 is not catalytically active it can only function by mediating protein-
protein interactions, where it plays a scaffold role. The effect of VRK3 on 
MAPK signaling has been characterized by its role in modulating nuclear 
signals mediated by ERK. ERK (extracellular regulated kinase) is a MAPK 
that has been implicated in the control of proliferation and cell growth [25, 
26]. ERK is the last kinase in the MAPK complex responding to EGF, 
ERBB2, Ras and Raf, which is most commonly assembled on the KSR1 
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scaffold. Activation of the pathway by growth factors (EGF) or oncogenes 
(ERBB2, RasG12V, or BRAFV600E) induces a phosphorylation of ERK (p-ERK) 
that has substrates in the cytosol and in the nucleus. Among its cytosolic 
targets is p90RSK (ribosomal S6 kinase) that activates pleiotropic response 
associated to cell growth and increase in cell mass [27]. The activated p-ERK 
is translocated to the nucleus and mainly phosphorylates a large number of 
transcription factors including ETS, ELK1, Pax6 or c-FOS among others, and 
their relative levels and activation might condition activation of one type of 
response or another. One of these pathways is represent by ERK 
(extracellular-signal regulated kinase). These kinases are regulated by 
phosphorylation and the level of phosphorylation is control by proteins 
known as mitogen-activated protein kinase phosphatases (MKPs), the 
expression or stabilization of MKP activity thus negatively controls ERK 
activation forming a feed-back regulatory mechanism [28]. In this context, 
the VRK3 protein, the least known member of the VRK family, appears to 
control the level of ERK activation [9, 29]. This effect is indirect and 
mediated by an interaction with the VHR (vaccinia H1-related). In the 
nucleus VHR dephosphorylates ERK resulting in its inactivation. The nuclear 
binding of VRK3 to VHR increases its phosphatase activity, and for this 
process the kinase activity is not necessary, thus this effect is postactivation 
in the cytosol and therefore its role is to mediate a downregulation, or 
silencing, the nuclear action of phospho-ERK [9, 29]. In this context, VRK3 
functions as a scaffold protein that binds to the VHR phosphatase, which 
removes the phosphate from an activated MAPK, as is the case of ERK, and 
thus inhibits or downregulates its nuclear signal.  
 
4. Modulation of transcription factors by VRK proteins 
 
4.1. VRK1 activation of transcription factors can cooperate or be 
an alternative to MAPK signals  
 
 Among the phosphorylation targets of hVRK1 there are transcription 
factors that are generally regulated by MAPK signaling. Some of these 
transcription factors can be directly phosphorylated by VRK1 and VRK2B 
isoform resulting in enhancement of their transcriptional activity, including   
c-Jun [30], ATF2 [31], CREB [32] and p53 [6]. The nature of these 
transcription factors reveals potential functional implications for VRK 
proteins. ATF2, CREB and c-Jun are members of the bZIP family of proteins 
that can bind to the AP-1 sites to regulate gene expression [33]; this 
activation is mediated by dimers of these proteins, and depending on the two 
partners the specificity of the gene selected can be determined. 
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 The c-Jun protein, a component of the AP1 transcription sites, is 
activated by phosphorylation by JNK (c-Jun N-terminal kinase) in response 
to stress signals that regulate apoptosis, proliferation and development [34, 
35]. The phosphorylation of c-Jun by VRK1 results in the transcriptional 
activation of Jun independently of the JNK signal. The oncogenic c-Jun can 
be directly phosphorylated by VRK1 and VRK2B in residues Thr63 and 
Ser73, which are the same as those phosphorylated by JNK (N-terminal 
kinase of c-Jun), activating c-Jun dependent transcription [30]. Thus, in 
situation of suboptimal stimulation, the two kinases might have an additive 
effect (Fig. 3) and reach maximum c-Jun transcriptional activation [30]. This 
generates an interesting situation in which c-Jun phosphorylation might be 
inhibited by the action of cytosolic VRK2A that blocks its activation as a 
consequence of VRK2A interaction with the JIP1 scaffold protein [24], thus 
the stress signal response is blocked, as is the case in hypoxia response [23], 
but at the same time permits its activation by a different route mediated by 
VRK1, which is regulated in a different way that remains to be identified, but 
which is associated with entry into cell cycle or responses to DNA damage. 
 
 
 
Figure 3. Diagram illustrating the different substrates identified for the human VRK1 
kinases and the overlap of its signals with other signaling pathways [6, 30-32]. 
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 The ATF2 and CREB transcriptions factors are implicated in pleiotropic 
responses. VRK1 phosphorylates ATF2 in Ser62 and Thr73 and activates 
transcription [31]. These two residues are very proximal to those targeted by 
JNK, Thr69 and Thr71; all within the same region (Fig. 3). These slightly 
different positions might regulate ATF2 by differential interaction properties 
with other transcriptional cofactors, and thus affect the specificity of gene 
transcription. Furthermore, these differences in phosphorylation target can 
generate a potential cooperative activation by suboptimal stimulation of each 
kinase, VRK1 and JNK, or respond alternatively to one signaling route or the 
other. But also the ATF2 residues targeted by VRK1 are the same as those 
targeted by calmodulin-dependent kinase IV or protein kinase A [31], 
permitting cooperation between more than one signaling pathways [31]. Thus 
at least four signaling routes can converge on ATF2 (Fig. 3). 
 Another target of VRK1 is CREB, a factor identified in response to 
cAMP. The CREB transcription factor can also be activated by 
phosphorylation in Ser133 by VRK1, and is required for transcription of 
cyclinD1 (CCND1), VRK1 forms part of the transcriptional complex of this 
gene in the G1 phase of the cell cycle. This CREB activation was previously 
known as an effect mediated by a cAMP-response element in CCND1 
promoter [32].  Thus two transcription factors responding to cAMP, ATF2 
and CREB, are regulated by VRK1, but the functional interaction between 
VRK1-mediated pathway and cAMP responses are not known. 
 
4.2. Regulation of p53 by VRK1, a novel regulatory loop between 
VRK1 and p53 in response to DNA damage mediated by DRAM 
 
 The tumor suppressor p53 was the first target identified for VRK 
proteins. VRK proteins can stabilize and regulate p53 by a unique 
phosphorylation of Thr18. VRK1 [6, 36] and VRK2 [12] phosphorylate p53 
specifically is Thr18, a residue that is critical to maintain the loop structure in 
its N-terminal tansactivation domain (TAD). The stabilization is a 
consequence of the disruption of the hydrogen bond between Thr18 and 
Asp21 in p53 necessary to maintain the structure of the loop that binds to 
Hdm2/Mdm2 [37, 38]. This Thr18 is the critical residue controlling the 
selection of binding partner by p53 TAD, its phosphorylation increases seven 
fold its binding to transcriptional coactivators, such as p300 [39], and 
dephosphorylated p53 interacts preferentially with Hdm2. The effect on p53 
interactions is very consistent with the consequences of phosphorylation; 
when p53 is phosphorylated in Thr18 there is a reduction in ubiquitination 
and an increase in acetylation, as well as in transcriptional activity [36]. This 
Thr18 specific phosphorylation changes by three orders of magnitude the 
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differential binding from Hdm2 to p300 and TAZ1 [39]. Other well-known 
residues such as Ser15 or Ser20 have a much weaker contribution to selection 
of binding partner and play a secondary role in this context, although they are 
the most characterized in response to DNA damage by the ATM/CHK2 [40, 
41]or ATR/CHK1 pathways [42].  
 The stabilization of p53 by VRKs renders a p53 molecule that cannot be 
degraded and thus accumulates in the cell; a persistent accumulation of p53 
will not permit life because it induces either a blockade of cell cycle 
progression or apoptosis. In addition, the VRK1 protein that functions as a 
p53 activator is very stable with a half life of four days thus if activated it 
will maintain p53 in a non-degradable and stabilized form. These 
characteristics suggested that regulation of VRK proteins level probably 
requires an active mechanism of protein degradation, which will permit p53 
downregulation at the same time. Therefore it is very likely that an 
autoregulation between p53 and VRK1 must exist. There was an initial 
observation which suggested that such potential mechanism was functioning 
because in cell lines that have a high level of p53 there was a lower level of 
VRK1 compared with cell lines that have a smaller amount of p53, and a 
higher level of VRK1 [43]. In experimental systems, overexpression of p53 
was always followed by a reduction in VRK1 level [43]. The drop in VRK1 
protein was not accompanied by a reduction in VRK1 gene expression 
suggesting it was an indirect effect of p53. Nevertheless, this downregulation 
was dependent on p53 transcriptional activity, probably by regulating the 
expression of a not yet identified protein that is the one that targets VRK1 for 
degradation [43]. 
 The structural requirements of the p53 molecule required to induce VRK 
downregulation have been identified using different p53 variants containing 
mutations, deletions or conformational mutants [43]. The N-terminal TAD 
(trans activation domain) was studied with the p53L22Q/23WS conformational 
mutant, phosphorylation mutants in all its Ser or Thr residues; none of them 
affected VRK1 downregulation  [43]. The p53 DNA binding domain was 
studied using the three most common mutations detected in sporadic or 
hereditary (Li-Fraumeni syndrome) human cancer. The conformational 
mutant p53R175H, or the p53R248W and p53R273H DNA-contact mutants. All 
these mutants were unable to induce downregulation of VRK1 levels [43]. 
Thus a functional p53 DNA binding domain is necessary and supports the 
requirement of p53 transcriptional dependence of this VRK1 downregulation. 
 The VRK1 protein is not ubiquitinated by Hdm2, or other ubiquitin 
ligases, as demonstrated by its insensitivity to either overexpression of mdm2 
or to proteasome inhibitors [43], suggesting that the proteasome pathway is 
not implicated in VRK1 downregulation. Alternatively, downregulation of 
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VRK1 is sensitive to inhibitors of late-endosome to lysosome transport such 
as chloroquine [43], and to inhibitors of lysosomal protease activity. These 
results suggested that p53 induces the expression of a protein that regulates 
VRK1 and targets it for lysosomal degradation.  This protein is DRAM, a 
lysosomal membrane protein of 238 aminoacids and has six transmembrane 
domains equally spaced [44]. DRAM expression is dependent on activation 
of transcription by p53, and expression is lost in case of common p53 
mutations in human cancer, such as p53R175H, p53R248W and p53R273H. These 
requirements are identical as those for VRK1 downregulation induced by 
p53, thus DRAM is a candidate to be its mediator, and its overexpression of 
DRAM downregulates VRK1. The induction of DNA damage by ultraviolet 
light results in accumulation of p53, followed by expression of DRAM and 
downregulation of VRK1. Thus p53 has a double autoregulatory loop to 
control its intracellular levels, activated p53 is phosphorylated and induces 
HDM2 and DRAM gene expression. But hdm2 ca not degrade p53 if it is 
phosphorylated, thus the removal of VRK1 by its lysosomal degradation 
mediated by DRAM permits the accumulation of unphosphorylated p53 that 
is now susceptible to ubiquitination by hdm2 and can be degraded in the 
proteasome (Fig. 4). 
 
 
 
Figure 4. Autoregulatory loop of VRK1 dependent on p53. Phosphorylated p53 
activates transcription of Mdm2 that downregulates p53 and of DRAM that 
downregulates VRK1. 
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5. VRK proteins in processes required for mitosis 
 
5.1. VRK1 expression and cell cycle 
 
 Expression of VRK1 and VRK2 was originally associated to 
proliferation, because of their expression in proliferating tissues such as 
testis, thymus, and fetal liver [2] and in the rapid proliferation stage of B-cell 
development in murine embryos [15].  
 The expression of human VRK1 gene is regulated in cell cycle 
progression. Serum withdrawal results in endogenous VRK1 gene silencing in 
human fibroblast, parallel to the loss of phopho-Rb, and also in loss of 
expression dependent on the human VRK1 gene promoter coupled to a 
luciferase reporter [45]. Addition of serum induces expression of VRK1 RNA 
at the same time as MYC, FOS and CCND1 (cyclinD1), indicating VRK1 is 
an early response gene. Knock-down of endogenous VRK1 results in lack of 
induction of cyclin D1 and a cell cycle block, early in G1 [36, 45]. 
 In human head and neck squamous cell carcinomas (HNSCC), VRK1 
protein is expressed at high levels and positively correlates with several 
proliferation markers such as Ki67, cyclins B1 and A, cdk2, cdk6 and cdc2. 
In addition in human lung carcinomas, there were higher levels of VRK1 in 
those tumors that have a p53 mutation, consistent with an inactivation of the 
p53 dependent autoregulatory loop [46]. 
 
5.2. VRK1, in the control of nuclear membrane formation 
 
 The VRK1 and VRK2 proteins, as well as the vaccinia virus B1R kinase, 
phosphorylate the BAF1 protein (barrier to autointegration factor 1), a 10 
kDa protein that forms dimers. The BAF1 protein binds to DNA in a non-
sequence specific manner [47], and to proteins containing LEM domains, 
which are present in the inner nuclear membrane [48]. VRKs and B1R 
phosphorylate residues Ser4 or Thr2/Thr3 in the N-terminal domain of BAF1. 
The phosphorylated BAF1 presents a reduction in its binding to DNA and 
LEM-containing proteins [49]. Phosphorylation of BAF1 in Ser4 delocalizes 
emerin and interferes with emerin binding to lamin A, both in mitosis and 
interphase [50]. The overexpression of VRKs reduces BAF1 interaction with 
nuclear chromatin and results in its dispersal [49]. Nuclear disassembly is a 
process necessary for cell cycle progression, thus BAF1 phosphorylation by 
VRK1 might be dependent on functional changes in the activity of VRK1, a 
kinase that is regulated in cell cycle, and required for G0 exit and G1 
progression [45], and its knock down causes a block of cell cycle progression 
[36, 45]. VRK1 is expressed as the cells enter the cycle from G0 to G1 and 
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the highest levels are achieved at G1/S transition [18]. The VRK1 protein is 
very stable and therefore is ready to act when the nuclear envelope has to 
disintegrate in order to permit chromosome segregation. The C. elegans   
Vrk-1 protein, a unique ortholog of human VRK proteins, also 
phosphorylates the BAF1 protein and affects nuclear membrane structure 
[51]. But C. elegans Vrk-1 protein is much larger, 610 aminoacids, 
completely unrelated to that of human VRK1 protein.. The conservation is 
restricted to the kinase domain, but there is no relation between their 
carboxyterminal regions. Thus C. elegans and human VRK1 have a common 
substrate, but probably a different regulation because of their different         
C-terminal region. Vaccinia virus B1R kinase also has among its substrates 
the BAF protein that is required in vaccinia life cycle at a time when 
disintegration of the nuclear envelope takes place, and this function can be 
partially rescued by overexpressed human VRK1 in virus with B1R 
mutations [49].  
  
5.3. Regulation of VRK1 activity by interaction with Ran and 
nuclear dynamics 
 
 The enzymatic activity of VRK1 can be regulated by different 
mechanisms that can affect either its kinase activity or its substrate 
specificity. These regulatory mechanisms include either protein interactions 
or covalent modifications. Using a proteomics based approach several 
interacting proteins have been identified and some of them have already been 
validated and are now components of emerging VRK signaling pathways. 
 The first allosteric regulator of VRK proteins is the small GTPase Ran, 
the only nuclear member of the large Ras GTPase family. Ran stably interacts 
with the three VRK proteins, but only the Ran interaction with VRK1 has 
been characterized [52]. Small GTPases have two forms depending on the 
bound nucleotide; inactive or bound to GDP, and active or bound to GTP. 
Ran-GDP is mostly located in the cytosol and participates in the nuclear 
transport mechanism; Ran-GTP, is located in the nucleus, and the nucleotide 
exchange from Ran-GDP to Ran-GTP is mediated by the action of RCC1 its 
GEF (Guanine exchange factor) in the nucleus. During mitosis Ran-GTP can 
form a concentration gradient, with the highest concentration near condensed 
chromosomes [53]. VRK1 contributes to chromatin condensation by 
phosphorylation of histone H3 [52, 54]. Ran-GTP binds to VRK1 but does 
not alter its activity, but VRK1 binding to Ran-GDP inhibits VRK1 kinase 
activity [52], permitting the formation of a nuclear gradient of VRK1 activity 
in the nucleus depending on its partner interactions. VRK1 will be activated 
near the chromosomes, where it can participate in chromatin condensation by 
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phosphorylation of histone H3 [54], a phosphorylation that is lost by 
knocked-down of VRK1 [52]. A diagram of the regulation of VRK1 by the 
Ran small GTPase is shown in Fig. 5. 
 Also some histones are substrates of VRK proteins. NHK (nucleosomal 
histone kinase), is the unique VRK ortholog in Drosophila melanogaster, and 
phosphorylates mitotic histones H2A which is required for acetylation of H3 
[55-57], a phosphorylation also required for mitotic progression [58]. Human 
VRK1 is able to phosphorylate histone H3 in Ser10 resulting in chromatin 
condensation, and cooperating with Aurora B, a process also required for 
progression of mitosis [54]; this phosphorylation of H3 can be inhibited if 
human VRK1 interacts with RanGDP [52]. 
 
 
 
Figure 5. Interaction between VRK1 and Ran. Effect on VRK1 kinase activity 
depending on the loading state of the small GTPase Ran. [52]. 
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5.5. The MEK-Plk3-VRK1 pathway: Specific phosphorylation of 
VRK1 in Golgi fragmentation 
 
 Golgi fragmentation is a necessary process during mitosis in order to 
redistribute this organelle into daughter cells. The regulation of this 
fragmentation is not well known, but mitogenic signals mediated by MAP 
kinases, particularly MEK1, that induce Golgi fragmentation [59-62], 
representing an upstream component. A step downstream of MEK1 is 
mediated by plk3 (polo-like kinase 3) [63], a member of the plk protein 
family [64]. There is a subpopulation of VRK1, detected with a specific 
antibody, which is partially located in Golgi colocalizing with markers such 
as giantin of GM130 [17], which suggests VRK1 might participate in 
processes regulating Golgi functions. VRK1 participates in this process as a 
downstream target of Plk3, since VRK1 has a consensus sequence for 
phosphorylation by Plk proteins. Plk3 phosphorylates VRK1 in Ser340 [17]. 
Knocking-down VRK1, or the use of a catalytically inactive VRK1K179E, 
blocks Golgi fragmentation induced by either MEK1 or Plk3 [17]. Thus, one 
of the cytosolic VRK1 roles is to contribute to Golgi fragmentation in G2/M 
in mitosis, as a new downstream step of this pathway in mitosis (Fig. 6). 
 
 
 
Figure 6. VRK1 is a downstream step in the signaling pathway required for Golgi 
fragmentation in mitosis [17]. 
 
Conclusions 
 
 VRK proteins are a group of new human serine-threonine kinases 
forming a distinctive branch in the human kinome. Among its targets there 
are a variety of transcription factors implicated in the response to DNA 
damage, such as p53, or stress responses such as p53 or c-Jun. VRK1 
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participate in several biological processes including regulation of cell cycle 
entry and progression, response to DNA damage, nuclear envelope assembly 
and Golgi fragmentation. VRK2 also modulates signaling by MAPK 
pathways playing and inhibitory role after its incorporation in a signalosome 
with scaffold proteins. The VRK signaling pathway is still partially 
characterized and is expected that its contribution to cell and tumor biology 
will increase significantly in a near future. 
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